Search research articles
Contact Us
Filters
Showing results (31-40 of 46) with videos related to
Page
of 5
Sort By:
Current Medical Research and Opinion
|
May 1, 2010
Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections
J Floris S Logman, Jennifer Stephens, Bart Heeg, et al.
European Urology Focus
|
April 9, 2018
Time-to-event Outcomes in Men with Nonmetastatic Castrate-resistant Prostate Cancer-A Systematic Literature Review and Pooling of Individual Participant Data
Markus Aly, Mahmoud Hashim, Bart Heeg, et al.
Pharmacoeconomics
|
January 19, 2006
Modelling the treated course of schizophrenia: development of a discrete event simulation model
Bart Heeg, Erik Buskens, Martin Knapp, et al.
Leukemia & Lymphoma
|
February 12, 2024
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison
Katja Weisel, Meletios A Dimopoulos, Meral Beksac, et al.
European Heart Journal. Quality of Care & Clinical Outcomes
|
April 25, 2021
Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies
Mark H Rozenbaum, Andrea Garcia, Daniel Grima, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
February 12, 2026
Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force
Sylwia Bujkiewicz, Oriana Ciani, Bart Heeg, et al.
Current Medical Research and Opinion
|
April 10, 2019
Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia
Jorge E Cortes, Bogdan Muresan, Carla Mamolo, et al.
Advances in Therapy
|
July 25, 2022
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
Jianming He, Heather Berringer, Bart Heeg, et al.
Journal of Comparative Effectiveness Research
|
September 12, 2022
Novel and existing flexible survival methods for network meta-analyses
Bart Heeg, Andrea Garcia, Sophie van Beekhuizen, et al.
Leukemia & Lymphoma
|
November 6, 2019
The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison
Maria-Victoria Mateos, Jesus San-Miguel, Hartmut Goldschmidt, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 46) with videos related to
Sort By:
Page
of 5
Current Medical Research and Opinion
|
May 1, 2010
Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections
J Floris S Logman, Jennifer Stephens, Bart Heeg, et al.
European Urology Focus
|
April 9, 2018
Time-to-event Outcomes in Men with Nonmetastatic Castrate-resistant Prostate Cancer-A Systematic Literature Review and Pooling of Individual Participant Data
Markus Aly, Mahmoud Hashim, Bart Heeg, et al.
Pharmacoeconomics
|
January 19, 2006
Modelling the treated course of schizophrenia: development of a discrete event simulation model
Bart Heeg, Erik Buskens, Martin Knapp, et al.
Leukemia & Lymphoma
|
February 12, 2024
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison
Katja Weisel, Meletios A Dimopoulos, Meral Beksac, et al.
European Heart Journal. Quality of Care & Clinical Outcomes
|
April 25, 2021
Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies
Mark H Rozenbaum, Andrea Garcia, Daniel Grima, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
February 12, 2026
Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force
Sylwia Bujkiewicz, Oriana Ciani, Bart Heeg, et al.
Current Medical Research and Opinion
|
April 10, 2019
Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia
Jorge E Cortes, Bogdan Muresan, Carla Mamolo, et al.
Advances in Therapy
|
July 25, 2022
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
Jianming He, Heather Berringer, Bart Heeg, et al.
Journal of Comparative Effectiveness Research
|
September 12, 2022
Novel and existing flexible survival methods for network meta-analyses
Bart Heeg, Andrea Garcia, Sophie van Beekhuizen, et al.
Leukemia & Lymphoma
|
November 6, 2019
The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison
Maria-Victoria Mateos, Jesus San-Miguel, Hartmut Goldschmidt, et al.
Page
of 5